This is an intermediate-level course that explores the molecular and genetic basis of cancer, its evolution, and cancer immunology.
This intermediate-level course is designed for a wide range of professionals, preferably with a background in bioscience, oncology, or any associated field, and capable of self-learning. Undergraduate or graduates and postgraduate scholars, researchers, academicians such as lecturers and professors, policymakers, and other industry professionals are likely to benefit from this course. This course will highly benefit researchers with an interest in oncology or stem cell research. Those looking for career opportunities in the field of cancer biology will also benefit.
Dr. Christos Evangelou
Ph.D. in Cancer Biology, Division of Molecular and Clinical Cancer Sciences, University of Manchester, UK. Areas of expertise include cancer immunology, melanoma research, cancer immunotherapy, and mechanisms of immunotherapy resistance. During my Ph.D. research, I studied the role of chronic inflammation and the cytokine IFN-gamma in adaptation and immunotherapy resistance in melanoma. By integrating high-throughput transcriptomic analyses and employing various cancer cell lines and animal models, I have developed methods to predict response to immunotherapy in melanoma patients. During my research, I have used the CRISPR/Cas9 system to knockout genes in human and mouse cell lines to assess the role of certain genes in immunotherapy resistance in melanoma.
Dr. Veronica Hughes
Veronica Hughes received her Ph.D. in medical science from the University of Florida. Her primary interest was cancer metastasis, dysregulation of the tumour microenvironment, and analysis of clinical trial design. Additionally, she engaged in the development of novel small animal models.
Dr. James Marchant
Ph.D. in Cardiac Physiology at the University of British Columbia. Investigating the role of the funny current in cardiac pacemaking and thermal tolerance in zebrafish using CRISPR genome editing technology.
Dr. Matthias Schröder
Ph.D. in Immunology at the Division of Immunopharmacology of the University Clinic of Frankfurt am Main. Involved in basic and applied research for immunological interventions to treat cancer for 13 years. Matthias used a high-throughput CRISPR/Cas9 approach to generate a library of knockout cells that could be differentiated into immunosuppressive cells to investigate the potential loss of function situations. Currently involved in the development of fusion proteins to activate receptors of the TNF-superfamily (CD40, CD27, etc.) at a small German Biotech company as Head of Assay Development.
We are proud to partner with the leading In2scienceUK as a step towards achieving our mission of imparting quality education and knowledge across the globe.
Train your employees and/or students in the most in demand topics, with CBEHx for Business and School.
The CBEHx for School domain empowers universities, schools, and other educational organizations with career-targeted transformative knowledge and skill development programs.
Grow better with the right option, click here to view pricing.
Usually, there are no general prerequisites when enrolling for any individual courses on cbehx.co.uk. However, some courses are certainly more advanced than others that are of introductory and intermediate level. For advanced-level courses, prior knowledge on the topic will be helpful for understanding complex concepts but not mandatory.
The relevant information about the suggested knowledge and background that might be helpful to follow each course is provided on the respective course registration page.
Yes, the courses are flexible and self-paced to suit your schedule. The term “self-paced” implies that the courses do not follow a pre-assigned schedule for learning within the course duration. You will be able to access all the course materials for each course that you have enrolled in as soon as the course begins.